Shire, the maker of Vyvanse, has filed for U.S. approval to treat adult attention-deficit/hyperactivity disorder with their new ADHD medication. Currently the product is approved for children ages 6 to 12 years with ADHD. The company says it has had positive results in their studies treating adults.
Read moreOne of our members recently posted this question on our Q & A board and I was hoping some of our members could offer some suggestions... Read more »
Last week, I posted, Marijuana for Bipolar: Treatment or Self-Medication?, which took its lead from MerelyMe’s piece on marijuana for... Read more »
Vyvanse, the daily medication to treat symptoms of attention-deficit/hyperactivity disorder, is now available in the United States. Vyvanse works... Read more »
The U.S. Food and Drug Administration has approved Vyvanse for the treatment of attention-deficit/hyperactivity disorder in adults. Vyvanse is a new... Read more »
Vyvanse is effective in treating adults with attention-deficit/hyperactivity disorder, according to new clinical trial results. In the study, 414... Read more »
Brand Name: Vyvanse Generic Name: lisdexamfetamine dimesylate Usage: Vyvanse has been approved by the Food and Drug Administration to treat... Read more »
The new attention-deficit/hyperactivity disorder (ADHD) medication Vyvanse has received another approval letter from the Food and Administration... Read more »